NCT02355535: Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies – Component 1

NCT02355535
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 85 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Any history of brain metastases
https://ClinicalTrials.gov/show/NCT02355535

Comments are closed.

Up ↑